Evidence map›Paper›PMID 39726608›Full record

ArticleFrontiers in immunology2024

Immunogenicity and protective efficacy of recombinant chimeric antigens based on surface proteins of

Maciej Chyb, Bartłomiej Tomasz Ferra, Malwina Kawka, Marta Skwarecka, Bożena Dziadek, Justyna Gatkowska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maciej ChybDepartment of Molecular Microbiology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Bartłomiej Tomasz FerraDepartment of Tropical Parasitology, Institute of Maritime and Tropical Medicine in Gdynia, Medical University of Gdansk, Gdynia, Poland.
Malwina KawkaDepartment of Molecular Microbiology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Marta SkwareckaPocket Diagnostics Poland, Gdansk, Poland.
Bożena DziadekDepartment of Molecular Microbiology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Justyna GatkowskaDepartment of Molecular Microbiology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Toxoplasmosis is caused by the opportunistic, cosmopolitan protozoan Methods: In this work, newly produced recombinant trivalent chimeric proteins of Results: The results of serological tests revealed a high level of serum IgG antibodies specific for the native Discussion: The obtained results demonstrate strong immunogenicity of the studied proteins and will allow to select candidates for further research aimed at increasing the immunoprotective properties of experimental vaccines against toxoplasmosis based on

Indexed as

Antibodies, ProtozoanAntigens, ProtozoanProtozoan ProteinsProtozoan VaccinesToxoplasmaAnimalsFemaleImmunogenicity, VaccineImmunoglobulin GMembrane ProteinsMiceRecombinant Fusion ProteinsToxoplasmosisToxoplasmosis, AnimalAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GMembrane ProteinsProtozoan ProteinsProtozoan VaccinesRecombinant Fusion Proteinsimmunoprotectionmurine experimental modelrecombinant chimeric antigenT. gondii experimental vaccineToxoplasma gondii

Identifiers

PMID39726608
PMCPMC11670819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.